Vaccine deployment characteristics and vaccine uptake

How to cite

Ashworth, Madison; Finnoff, David; Cherry, Todd; Newbold, Stephen; Thunstrom, Linda. 2020. "Vaccine deployment characteristics and vaccine uptake." AEA RCT Registry. AEARCTR-0006884. https://doi.org/10.1257/rct.6884-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Madison Ashworth* , David Finnoff , Todd Cherry , Stephen Newbold , Linda Thunstrom

* Primary investigator

Registry ID
AEARCTR-0006884
DOI
https://doi.org/10.1257/rct.6884-1.0
First registered
Last updated
Status
In development
Trial dates
2020-12-11 – 2021-01-01
Countries
United States of America (Wyoming)
Registry record
http://www.socialscienceregistry.org/trials/6884

Abstract

Growing vaccine hesitancy is a well-documented trend, which may affect the uptake of COVID-19 vaccine. This study aims to determine vaccine uptake across a range of characteristics of the virus and the vaccine. We will conduct a survey in which we vary the value of key parameters, such as (i) the duration of clinical development, (ii) the risk of side effects, (iii) the prevalence of the virus, the vaccine uptake rate once available, and (iv) the reported effectiveness of the vaccine in protecting people from becoming infected. We will determine the proportion of the population that would be willing to take the COVID-19 vaccine right away and 6 months after the vaccine has been available. We will also include an information treatment that informs participants of the rigor of the vaccine trials.

Intervention

We will conduct a survey in which we vary the value of key parameters, such as (i) the duration of clinical development, (ii) the risk of side effects, (iii) the prevalence of the virus, the vaccine uptake rate once available, and (iv) the reported effectiveness of the vaccine in protecting people from becoming infected. We will determine the proportion of the population that would be willing to take the COVID-19 vaccine right away and 6 months after the vaccine has been available. We will also include an information treatment that informs participants of the rigor of the vaccine trials.

Experimental design

Participants will be randomized into 1 of 32 treatments which varies vaccine characteristics (side effect rate, effectiveness, and duration of the clinical trial), the number of individuals infected with COVID-19 at the time, and level of information given regarding the vaccine approval process. Participants would be asked about their willingness to take a COVID-19 vaccine under the conditions described in the treatment. If they state they would not take the vaccine they are randomized into 1 of 16 follow up treatments where they will be asked if they would take the vaccine 6 months later given revised side effect rates, vaccine effectiveness, and number previously infected with COVID-19. The percent of the U.S. population that has taken the vaccine in the 6 months will also be varied.
Participants will be asked about the risk factors for contracting the virus, their response to a positive COVID-19 test, and their trust in different information sources.

Design details

Randomization method
Randomization done by computer.
Randomization unit
Individual
Clusters
0
Observations
3000
Arms
93 per initial treatment and maximum of 5 in follow-up treatments.
Primary outcomes
The proportion of the population that would be willing to take the COVID-19 vaccine right away and 6 months after the vaccine has been available.

Cited by

No citation data available for this registration yet.

Keywords